What SDD Actually Does
SDD involves applying antibiotic gels directly inside the mouth and stomach, plus giving intravenous (IV) antibiotics for the first four days of mechanical ventilation. The idea is straightforward: kill off harmful bacteria in the gut before they get a chance to spread to the lungs or bloodstream.
Think of it like clearing a clogged storm drain before heavy rain. If you remove the blockage early, the flood damage downstream is reduced.
Some earlier European studies suggested SDD could cut deaths in the ICU. But those studies were smaller and conducted in specific hospital environments. The big, definitive trial had not yet been done.
The Biggest Test Yet
Researchers randomly assigned 26 ICUs across Australia and Canada to either use SDD or continue with standard care. Nearly 9,300 patients were enrolled in the main trial, and an additional 10,700 patients were tracked in a separate observational assessment to monitor broader effects on bacterial resistance across each ICU.
This was not a small experiment. With almost 20,000 patients involved, it is one of the most ambitious ICU trials ever completed. The primary question: does SDD prevent death?
At 90 days, 27.9% of patients in the SDD group had died — compared to 29.5% in the standard-care group. That's a difference of about 1.6 percentage points, which sounds meaningful, but the statistical analysis showed it was not significant enough to count as a real effect. The odds ratio was 0.94, with a confidence interval that crossed 1.0 — meaning the result could easily be due to chance.
In plain terms: the trial could not prove that SDD saves lives.
But that's not the end of the story.
Where SDD Did Make a Difference
The results were more positive when researchers looked at infection outcomes. Bloodstream infections occurred in 4.9% of SDD patients compared to 6.8% of standard-care patients — a meaningful reduction. Even more striking: antibiotic-resistant bacteria were found in 16.8% of SDD patients versus 26.8% in the standard-care group. That's a 10-percentage-point difference.
These are not trivial numbers. Bloodstream infections and antibiotic-resistant bacteria are serious threats in the ICU. Reducing them matters enormously for patient quality of care, even if the overall death rate didn't shift.
The Antibiotic Resistance Problem
Here's the catch that makes this complicated. While SDD appeared to reduce resistant bacteria within individual patients, the broader ecological assessment — the one tracking resistance patterns across entire ICUs — did not confirm that SDD was non-inferior (meaning it couldn't be confirmed as no worse than standard care) for resistance at the unit level.
This is important. If using antibiotics routinely in the ICU causes wider resistance patterns to worsen across the hospital, any benefit to individual patients could be undone over time. Antibiotic resistance is one of the most pressing global health threats. Any treatment that uses antibiotics routinely must be evaluated through that lens.
What This Means for ICU Families and Patients
If you or a loved one is in the ICU on a ventilator, this study is relevant context — not a call to action. SDD is not standard care in most hospitals outside parts of Europe, and this trial is unlikely to change that status in the near term.
The findings do suggest that SDD reduces certain infections, but it doesn't change survival odds in a measurable way. Families navigating ICU decisions should focus their conversations with medical teams on overall goals of care, not on requesting or refusing SDD specifically.
Honest Limits of This Trial
The trial enrolled patients across Australia and Canada, and results may differ in other healthcare systems with different baseline rates of antibiotic resistance. ICUs in Europe — where SDD has been more widely used — were not included. The study was also conducted during the COVID-19 pandemic, which may have affected some outcomes in ways that are difficult to separate.
What Happens Now
This trial will not close the debate. Researchers and intensivists (ICU specialists) will continue to argue about whether SDD might benefit specific patient subgroups, or whether modified versions of the protocol could improve results. The antibiotic resistance question demands further study — particularly in healthcare environments where resistance rates are already high.
The science of protecting critically ill patients from infection is far from finished. But this trial sends a clear message: a treatment that reduces infections must still prove it actually keeps more people alive before it becomes standard practice.
